Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Observation of disorder-free localization using a (2+1)D lattice gauge theory on a quantum processor.

Science (New York, N.Y.)·2026
Same author

Visualizing dynamics of charges and strings in (2 + 1)D lattice gauge theories.

Nature·2025
Same author

Scaling and logic in the colour code on a superconducting quantum processor.

Nature·2025
Same author

NETest® 2.0-A decade of innovation in neuroendocrine tumor diagnostics.

Journal of neuroendocrinology·2025
Same author

Thermalization and criticality on an analogue-digital quantum simulator.

Nature·2025
Same author

Radiographic calibration for pubic diastasis assessment in bladder exstrophy-epispadias complex: a phantom study.

Pediatric radiology·2024
Same journal

Severe tricuspid regurgitation is a congestion-driven cardiorenal disease: A longitudinal study defining a right heart failure phenotype.

International journal of cardiology·2026
Same journal

Applicability of ischemic heart disease clinical practice guidelines in low- and middle-income countries.

International journal of cardiology·2026
Same journal

Effectiveness of a new diagnostic algorithm for the diagnosis of unexplained syncope in patients with hypertrophic cardiomyopathy.

International journal of cardiology·2026
Same journal

The predictive role of the FIB-4 index in identifying arrhythmic risk among patients with nonischemic dilated cardiomyopathy.

International journal of cardiology·2026
Same journal

Beyond arrhythmias: Exploring heart failure in arrhythmogenic cardiomyopathy.

International journal of cardiology·2026
Same journal

Corrigendum to "First-in-human study of the K-Clip™ transcatheter annular repair system for severe functional tricuspid regurgitation" [International Journal of Cardiology 390(2023) / IJCA 131174].

International journal of cardiology·2026
See all related articles

Related Experiment Videos

Carcinoid heart disease.

B I Gustafsson1, O Hauso, I Drozdov

  • 1Department of Gastroenterological Surgery, Yale University School of Medicine New Haven, CT06520-8062, USA.

International Journal of Cardiology
|June 24, 2008
PubMed
Summary
This summary is machine-generated.

Carcinoid heart disease (CHD) involves heart valve dysfunction due to neuroendocrine tumors. Improved survival is noted, but the link between tumor markers and longevity in CHD needs further study.

Related Experiment Videos

Area of Science:

  • Cardiology
  • Oncology
  • Biochemistry

Background:

  • Carcinoid syndrome, often from liver metastasis of neuroendocrine tumors, affects 40% of patients with carcinoid heart disease (CHD).
  • Serotonin (5-HT) is implicated in the fibrotic process leading to CHD, primarily affecting right-sided heart valves (tricuspid and pulmonary).
  • Left-sided valvular involvement and coronary vasospasm occur in a minority of CHD patients.

Purpose of the Study:

  • To review the pathophysiology, diagnosis, and treatment of carcinoid heart disease.
  • To analyze the impact of therapeutic advances on patient survival.
  • To investigate the correlation between tumor markers and long-term survival in CHD.

Main Methods:

  • Literature review of carcinoid syndrome and carcinoid heart disease.
  • Analysis of echocardiographic findings in CHD.
  • Review of therapeutic outcomes, including valve replacement and survival data.

Main Results:

  • Echocardiography shows characteristic valve immobility, thickening, and retraction, leading to tricuspid regurgitation and pulmonary stenosis.
  • Surgical mortality for valve replacement has decreased from >20% to <10% due to technical advances and earlier diagnosis.
  • Median survival in CHD patients has increased from 1.5 to 4.4 years over two decades, potentially due to multimodal treatment approaches.

Conclusions:

  • Carcinoid heart disease requires specific diagnostic and therapeutic strategies, with valve replacement becoming more feasible.
  • While overall survival has improved, a definitive correlation between reduced tumor markers and enhanced long-term survival in CHD remains to be rigorously established.